Understanding the checkpoint blockade in lung cancer immunotherapy

2017 ◽  
Vol 22 (8) ◽  
pp. 1266-1273 ◽  
Author(s):  
Maria Giovanna Dal Bello ◽  
Angela Alama ◽  
Simona Coco ◽  
Irene Vanni ◽  
Francesco Grossi
2020 ◽  
Vol 20 (2) ◽  
Author(s):  
Novita Andayani ◽  
Linda Julisafrida

Abstrak. Kanker paru masih menjadi masalah kesehatan secara menyeluruh, baik di dunia maupun di Indonesia, khususnya di Aceh. Saat ini kanker paru masih menjadi penyebab kematian tertinggi di dunia.  Berbagai peneletian tentang tatalaksana kanker paru telah dikembangkan, perkembangan terapi kanker paru saat ini berupa immunoterapi yang menargetkan reseptor penghambat sel T, seperti program sel death (PD-1) , terapi checkpoint blockade, immunoterapi baru berdasarkan neoantigen selektif dengan tujuan pengobatan mampu mendorong sel yang di transformasikan.Immunoterapi adalah salah satu metode pengobatan berbagai jenis tumor dengan efek samping yang dapat di atasi. Tujuan imunoterapi kanker adalah memberikan efektor antitumor (antibodi dan sel T ) terhadap pasien. Perkembangan ilmu pengetahuan tentang tatalaksana kanker berkembang sangat pesat, baik yang bersifat invasif maupun yang non invasif hingga penatalaksaan nano molekul. Tujuan pengobatan beruapa peningkatan kualitas hidup dan peningkatan survival rate.Kata Kunci : kanker paru, immunoterapi, PD-1, PD-L1, checkpoint blockadeAbstract. Lung cancer is still a comprehensive health problem, both in the world and in Indonesia, especially in Aceh. Currently lung cancer is still the highest cause of death in the world. Various studies on the management of lung cancer have been developed, the development of lung cancer therapy currently in the form of immunotherapy that targets T cell receptor inhibitors, such as the cell death program (PD-1), checkpoint blockade therapy, new immunotherapy based on selective neoantigens with the aim of treatment being able to encourage cells that transformed.Immunotherapy is one method of treating various types of tumors with side effects that can be overcome. The aim of cancer immunotherapy is to provide antitumor effectors (antibodies and T cells) to patients. The development of science about cancer management is developing very rapidly, both invasive and non-invasive to the management of nano molecules. Treatment goals include improving the quality of life and increasing survival rates.Keyword: lung cancer, immunotherapy, PD-1, PD-L1, checkpoint blockade


2020 ◽  
Vol Volume 12 ◽  
pp. 5975-5985
Author(s):  
Peng Song ◽  
Dongliang Yang ◽  
Xiaoxia Cui ◽  
Hanping Wang ◽  
Xiaoyan Si ◽  
...  

2021 ◽  
pp. jim-2021-001806
Author(s):  
Hannah Elizabeth Green ◽  
Jorge Nieva

The advent of checkpoint blockade-based immunotherapy is rapidly changing the management of lung cancer. Whereas past anticancer drugs’ primary toxicity was hematologic, the newer agents have primarily autoimmune toxicity. Thus, it is no longer enough for oncology practitioners to be skilled only in hematology. They must also understand management of autoimmune conditions, leveraging the skills of the rheumatologist, endocrinologist and gastroenterologist in the process. Herein we describe the mechanism of action and toxicities associated with immune checkpoint blockade in patients with lung cancer and provide a framework for management of adverse events.


2020 ◽  
Vol 3 (6) ◽  
pp. 1900200
Author(s):  
Ching‐Hsin Huang ◽  
Natalie Mendez ◽  
Oscar Hernandez Echeagaray ◽  
Joi Weeks ◽  
James Wang ◽  
...  

The Lancet ◽  
2019 ◽  
Vol 394 (10212) ◽  
pp. 1904-1905
Author(s):  
Tony S K Mok ◽  
Jin Zhang ◽  
Gilberto Lopes

Sign in / Sign up

Export Citation Format

Share Document